

Henry S Friedman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1238965/publications.pdf>

Version: 2024-02-01

136
papers

7,730
citations

101543

36
h-index

53230

85
g-index

139
all docs

139
docs citations

139
times ranked

8545
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial. <i>Supportive Care in Cancer</i> , 2022, 30, 3463-3471.	2.2	3
2	A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2022, 40, e14015-e14015.	1.6	5
3	Reproducibility of outcomes in sequential trials using CMV-targeted dendritic cell vaccination for glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2005-2005.	1.6	5
4	A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2076-TPS2076.	1.6	0
5	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.	12.8	77
6	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. <i>Neuro-Oncology Practice</i> , 2021, 8, 299-309.	1.6	5
7	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 631618.	2.8	0
8	LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2065-TPS2065.	1.6	5
9	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. <i>CNS Oncology</i> , 2021, 10, CNS77.	3.0	3
10	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. <i>Supportive Care in Cancer</i> , 2020, 28, 2229-2238.	2.2	9
11	Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. <i>Journal of Neuro-Oncology</i> , 2020, 147, 477-483.	2.9	4
12	Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2566-2566.	1.6	4
13	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. <i>Complementary Therapies in Clinical Practice</i> , 2019, 36, 43-48.	1.7	5
14	Singleâ€institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. <i>Health Science Reports</i> , 2019, 2, e114.	1.5	10
15	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. <i>Cancer Research</i> , 2019, 79, 3383-3394.	0.9	30
16	Second primary cancers in long-term survivors of glioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 386-391.	1.6	12
17	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz036.	0.7	4
18	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2019, 78, 57-64.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. Journal of Clinical Oncology, 2019, 37, 2060-2060.	1.6	2
20	Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.. Journal of Clinical Oncology, 2019, 37, e13526-e13526.	1.6	8
21	Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. Oncologist, 2018, 23, 889-e98.	3.7	26
22	Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Oncologist, 2018, 23, 157-e21.	3.7	44
23	Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. Journal of Neuro-Oncology, 2018, 137, 349-356.	2.9	49
24	Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. Journal of Neuro-Oncology, 2018, 138, 489-498.	2.9	5
25	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Research, 2018, 78, 256-264.	0.9	82
26	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. Cancer Research, 2018, 78, 36-50.	0.9	35
27	Adjunctive perampanel for glioma-associated epilepsy. Epilepsy & Behavior Case Reports, 2018, 10, 114-117.	1.5	26
28	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. Neuro-Oncology, 2018, 20, i93-i93.	1.2	2
29	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nature Communications, 2018, 9, 2087.	12.8	124
30	Recurrent Glioblastoma Treated with Recombinant Poliovirus. New England Journal of Medicine, 2018, 379, 150-161.	27.0	570
31	A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. Therapeutics and Clinical Risk Management, 2017, Volume 13, 33-40.	2.0	6
32	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research, 2017, 23, 1898-1909.	7.0	215
33	A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26373.	1.5	25
34	A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population. Journal of Neuro-Oncology, 2017, 134, 363-369.	2.9	18
35	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. Journal of Clinical Oncology, 2017, 35, e13533-e13533.	1.6	0
36	Reductions in exercise behavior and tumor progression in newly diagnosed glioblastoma (GBM) patients.. Journal of Clinical Oncology, 2017, 35, e21636-e21636.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2061.	1.6	17
38	Phase I trial of combination of antitumor immunotherapy targeted against <i>cytomegalovirus</i> (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2016, 34, e13518-e13518.	1.6	6
39	Baseline cognitive function to predict survival in patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10125-10125.	1.6	1
40	QOL-21DIET AND HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN THE PRIMARY BRAIN TUMOR POPULATION. <i>Neuro-Oncology</i> , 2015, 17, v192.3-v192.	1.2	0
41	Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. <i>Oncologist</i> , 2015, 20, 727-728.	3.7	32
42	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	27.8	429
43	Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide. <i>Cancer Immunology Research</i> , 2015, 3, 320-325.	3.4	20
44	Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2034-2034.	1.6	4
45	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2068-2068.	1.6	9
46	Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2067-2067.	1.6	0
47	Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2015, 33, e13004-e13004.	1.6	0
48	Psychosocial distress and its effects on the health-related quality of life of primary brain tumor patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9553-9553.	1.6	1
49	Secondary cancers in long-term survivors of primary glioblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20616-e20616.	1.6	0
50	Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).. <i>Journal of Clinical Oncology</i> , 2015, 33, e13030-e13030.	1.6	0
51	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. <i>Nature Genetics</i> , 2014, 46, 726-730.	21.4	148
52	Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS2106-TPS2106.	1.6	1
53	Single-institution retrospective review of newly diagnosed glioblastoma (GBM) patients (pts) treated on bevacizumab (BEV) in clinical practice.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2082-2082.	1.6	0
54	Long-term survivorship in adult primary glioblastoma: Clinical and neurological outcomes of a large, single-center study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9519-9519.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2014, 32, 3069-3069.	1.6	0
56	Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.. Journal of Clinical Oncology, 2013, 31, e13015-e13015.	1.6	1
57	Analysis of high-dose methotrexate with rituximab versus other treatment regimens for primary central nervous system (CNS) lymphoma.. Journal of Clinical Oncology, 2013, 31, 2090-2090.	1.6	0
58	Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2094-2094.	1.6	4
59	CNS Oncology: reflecting a rapidly changing landscape. CNS Oncology, 2012, 1, 1-2.	3.0	0
60	Frequent <i>ATRX</i> , <i>CIC</i> , <i>FUBP1</i> and <i>IDH1</i> mutations refine the classification of malignant gliomas. Oncotarget, 2012, 3, 709-722.	1.8	532
61	Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.. Journal of Clinical Oncology, 2012, 30, 2027-2027.	1.6	1
62	Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).. Journal of Clinical Oncology, 2012, 30, 2074-2074.	1.6	2
63	Phase II study of bevacizumab plus irinotecan and carboplatin for recurrent WHO grade 3 malignant gliomas with no prior bevacizumab failure.. Journal of Clinical Oncology, 2012, 30, 2095-2095.	1.6	0
64	Safety and efficacy of the addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma multiforme.. Journal of Clinical Oncology, 2012, 30, 2094-2094.	1.6	15
65	The addition of bevacizumab to temozolomide and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM).. Journal of Clinical Oncology, 2012, 30, 2090-2090.	1.6	1
66	Exercise Behavior, Functional Capacity, and Survival in Adults With Malignant Recurrent Glioma. Journal of Clinical Oncology, 2011, 29, 2918-2923.	1.6	107
67	Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology, 2009, 27, 4733-4740.	1.6	2,219
68	Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. Journal of Neuro-Oncology, 2009, 95, 129-134.	2.9	47
69	Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Journal of Neuro-Oncology, 2009, 95, 393-400.	2.9	53
70	Introduction: Irinotecan in brain tumors. Cancer, 2003, 97, 2351-2351.	4.1	0
71	The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer, 2003, 97, 2359-2362.	4.1	37
72	Cellular Mechanisms of Cyclophosphamide Resistance: Model Studies in Human Medulloblastoma Cell Lines. Cancer Treatment and Research, 2002, 112, 199-209.	0.5	6

#	ARTICLE	IF	CITATIONS
73	O6-benzylguanine-mediated enhancement of chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 943-8.	4.1	67
74	Activity of iriflufen (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 413-416.	2.3	14
75	Long term response in a patient with neoplastic meningitis secondary to melanoma treated with ¹³¹ I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab') ₂ . <i>Cancer</i> , 2001, 91, 1809-1813.	4.1	35
76	Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke. <i>Journal of Neuro-Oncology</i> , 2000, 46, 151-156.	2.9	11
77	Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 345-349.	2.3	31
78	O ⁶ -Benzylguanine-mediated enhancement of nitrosourea activity in Merck central nervous system tumor xenografts - implications for clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 437-440.	2.3	18
79	Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study. <i>Journal of Neuro-Oncology</i> , 1999, 43, 43-47.	2.9	42
80	Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. <i>Journal of Neuro-Oncology</i> , 1999, 44, 233-241.	2.9	18
81	Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 73-79.	2.3	17
82	Modulation of cyclophosphamide activity by O ⁶ -alkylguanine-DNA alkyltransferase. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 80-85.	2.3	47
83	Topotecan treatment of adults with primary malignant glioma. <i>Cancer</i> , 1999, 85, 1160-1165.	4.1	65
84	Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: A pediatric oncology group study. <i>Annals of Neurology</i> , 1998, 44, 313-316.	5.3	113
85	Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas. , 1998, 30, 75-80.		14
86	Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): Preliminary results. , 1998, 31, 16-18.		22
87	Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 485-490.	2.3	57
88	Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 479-482.	2.3	17
89	Modulation of Melphalan Resistance in Glioma Cells with a Peripheral Benzodiazepine Receptor Ligand ^α Melphalan Conjugate. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 1726-1730.	6.4	32
90	Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 409-414.	2.3	6

#	ARTICLE	IF	CITATIONS
91	False positive images in the follow-up of patients with brain tumors. , 1997, 28, 127-131.		8
92	Ubiquitination-Dependent Proteolysis of O ⁶ -Methylguanine-DNA Methyltransferase in Human and Murine Tumor Cells following Inactivation with O ⁶ -Benzylguanine or 1,3-Bis(2-chloroethyl)-1-nitrosourea. Biochemistry, 1996, 35, 1328-1334.	2.5	203
93	Carboplatin pharmacokinetics in young children with brain tumors. Cancer Chemotherapy and Pharmacology, 1996, 38, 395-400.	2.3	13
94	Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. , 1996, 26, 105-110.		56
95	Treatment of patients with pineoblastoma with high dose cyclophosphamide. , 1996, 26, 387-392.		23
96	Successful treatment of childhood pilocytic astrocytomas metastatic to the leptomeninges with high-dose Cyclophosphamide. Medical and Pediatric Oncology, 1996, 27, 32-39.	1.0	45
97	Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy: Clinical characteristics and treatment related toxicities. Cancer, 1996, 77, 555-562.	4.1	90
98	Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis?. , 1996, 78, 874-880.		45
99	Microsatellite analysis of childhood brain tumors. , 1996, 15, 54-63.		40
100	Fabrication and testing of a device capable of reducing the incidence of ventricular shunt promoted metastasis. Journal of Neuro-Oncology, 1996, 27, 39-46.	2.9	10
101	Treatment of infants with malignant gliomas: The Pediatric Oncology Group Experience. Journal of Neuro-Oncology, 1996, 28, 245-56.	2.9	91
102	Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy: Clinical characteristics and treatment related toxicities. Cancer, 1996, 77, 555-562.	4.1	4
103	Microsatellite analysis of childhood brain tumors. Genes Chromosomes and Cancer, 1996, 15, 54-63.	2.8	3
104	Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Medical and Pediatric Oncology, 1995, 25, 38-44.	1.0	63
105	Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. Medical and Pediatric Oncology, 1995, 25, 190-196.	1.0	29
106	Prognostic implications of chromosome 17p deletions in human medulloblastomas. Journal of Neuro-Oncology, 1995, 24, 39-45.	2.9	123
107	Cyclophosphamide therapy of medulloblastoma: From the laboratory to the clinic and back again (and again and again). Journal of Neuro-Oncology, 1995, 24, 103-108.	2.9	12
108	Phase I studies of treatment of malignant gliomas and neoplastic meningitis with ¹³¹ I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?)2-a preliminary report. Journal of Neuro-Oncology, 1995, 24, 109-122.	2.9	125

#	ARTICLE	IF	CITATIONS
109	Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. <i>Journal of Neuro-Oncology</i> , 1995, 25, 9-17.	2.9	16
110	A phase II study of every other day high-dose ifosfamide in pediatric brain tumors. <i>Journal of Neuro-Oncology</i> , 1995, 25, 77-84.	2.9	27
111	The effect of l-amino acid oxidase on activity of melphalan against an intracranial xenograft. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 379-384.	2.3	3
112	Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 393-403.	2.3	331
113	Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 36, 393-403.	2.3	31
114	Cerebral atrophy in an infant following treatment with ifosfamide. <i>Medical and Pediatric Oncology</i> , 1994, 23, 380-383.	1.0	13
115	Biodistribution of O 6-benzylguanidine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 35, 121-126.	2.3	15
116	Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 171-174.	2.3	78
117	Chemotherapy for pilocytic astrocytomas. <i>Cancer</i> , 1993, 71, 3165-3172.	4.1	50
118	Preradiation chemotherapy in advanced medulloblastoma a pediatric oncology group pilot study. <i>Cancer</i> , 1993, 72, 2755-2762.	4.1	58
119	Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma. <i>Medical and Pediatric Oncology</i> , 1993, 21, 301-306.	1.0	37
120	False-positive MRI detection of recurrent or metastatic pediatric infratentorial tumors. <i>Medical and Pediatric Oncology</i> , 1993, 21, 350-355.	1.0	6
121	Reversal of radiation-induced neutropenia by granulocyte colony-stimulating factor. <i>Medical and Pediatric Oncology</i> , 1992, 20, 240-242.	1.0	36
122	Osteoblastic metastases from astrocytomas: A report of two cases. <i>Medical and Pediatric Oncology</i> , 1991, 19, 318-324.	1.0	20
123	Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 15-21.	2.3	11
124	Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 27, 278-284.	2.3	8
125	Medulloblastoma: tumor biological and clinical perspectives. <i>Journal of Neuro-Oncology</i> , 1991, 11, 1-15.	2.9	59
126	Familial erythrophagocytic lymphohistiocytosis: Late relapse despite continuous high-dose VP-16 chemotherapy. <i>Medical and Pediatric Oncology</i> , 1990, 18, 27-29.	1.0	12

#	ARTICLE	IF	CITATIONS
127	Papillary adenocarcinoma of the renal pelvis in a child: Case report and brief review of the literature. <i>Medical and Pediatric Oncology</i> , 1990, 18, 81-86.	1.0	15
128	Selection of a management strategy for pediatric brainstem tumors. <i>Medical and Pediatric Oncology</i> , 1989, 17, 116-125.	1.0	43
129	Childhood hepatic mesenchymoma: Successful treatment with surgery and multiple-agent chemotherapy. <i>Medical and Pediatric Oncology</i> , 1988, 16, 62-65.	1.0	34
130	Transient Late Magnetic Resonance Imaging Changes Suggesting Progression of Brain Stem Glioma: Implications for Entry Criteria for Phase II Trials. <i>Neurosurgery</i> , 1988, 23, 248-253.	1.1	9
131	The Localisation of Radiolabeled Murine Monoclonal Antibody 81C6 and its Fab Fragment in Human Glioma Xenografts in Athymic Mice. <i>British Journal of Neurosurgery</i> , 1988, 2, 179-191.	0.8	19
132	Bacterial Endocarditis in a Child with a Broviac Catheter. <i>Pediatric Hematology and Oncology</i> , 1987, 4, 131-136.	0.8	3
133	Treatment of lymphohistiocytic erythrophagocytosis with VP-16 and aziridinybenzoquinone. <i>Medical and Pediatric Oncology</i> , 1987, 15, 58-61.	1.0	9
134	Severe Mycoplasma Pneumonia in Three Sisters with Sickle Cell Disease. <i>Pediatric Hematology and Oncology</i> , 1986, 3, 259-265.	0.8	8
135	Criteria and definitions for response and relapse in children with brain tumors. <i>Cancer</i> , 1985, 56, 1824-1826.	4.1	34
136	Propionibacterium shunt nephritis in two adolescents with medulloblastoma. <i>Cancer</i> , 1983, 52, 330-333.	4.1	13